PSGB&I Agenda Thursday

08:30 –9:00

Registration

0900 –0920

UK-EDI: Detecting pancreatic cancer in patients with diabetes Prof Eithne Costello

0920 - 0940

A UK wide Optimal Care Pathway for pancreatic cancer Dr Georgia Papacleovoulou

0940 – 0955

PANCARER The impact of pancreatic cancer diagnosis and
treatment on caregivers of patients Mr Sanjay Pandanaboyana

0955 – 1015

The National HPB Nursing Group: The Clinical Nurse Specialist Role In Pancreatic Cancer - Celebrating evolution, autonomy and collaboration Phil Whelan, Nurse Consultant.  

11:00-11:20

Obstructive Jaundice treatment: Any tool for any Job? Dr Martin James

11.20 - 11:30

MDT Debate; What do I bring to the table. Mr Glen Irving, Dr Naomi Hersey & Dr Martin James

11:30-11.50

The current and future non-surgical oncology options of
Pancreatic Cancer – a UK perspective Dr Ganesh Radnakrishna

12:30-13:40

Session 3 Pancreatic Cancer Team Approach from Bench to bedside                Chairs Mr Benjamin Huntley & Prof Bill Greenhalf

State of the Art Lecture: Identification of phenotypes following neoadjuvant chemotherapy a pathway for new therapies for PDAC Dr Peter Bailey

1400 – 1415

EUS Guided Radio Frequency Ablation of tumours: where are we at? Dr Sudarshan Kadri 

1415 – 1430

The future landscape of pancreatic cancer imaging – PACT-UK, NCITA biobank and Al   Mr John Moir

1430 – 1445

 Post operative pancreatic fistula improving outcomes  Prof Keith Roberts

14:50-15:30

Session 4 Lord Smith Medal Abstract Presentations: Session 1 Chairs Mr Ahmed Al-Mukhtar & Dr Mary Phillips

1530 – 1630

Lord Smith Medal Abstract Presentations: Session 1

1. 15:30 The value of PET/CT for predicting neoadjuvant therapy response and survival in borderline resectable and locally-advanced PDAC: analysis of the largest UK study population Yazan Khaled, Leeds Institute of Medical Research.

2. 15:40  Illuminating pancreatic cancer therapy: novel fluorescent nanoparticle for precision surgery Yazan Khaled, Leeds Institute of Medical Research.

3. 15:50 Multiomic spatial modelling of pancreatic IPMN reveals distinct immune cell distribution: mapping the transcriptomic landscape via regional bulk, single-cell and subcellular approaches. Andrew Cameron Glasgow Royal Infirmary / University of Glasgow

4. 16:00 Invasive intraductal oncocytic papillary neoplasms (IOPN) and adenocarcinomas arising from Intraductal papillary mucinous neoplasms (IPMN): adjuvant chemotherapy, patterns of recurrence and survival. James Lucocq NHS Lothian

5. 16:10 Risk of recurrence after surgical resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia (IPMN) with patterns of distribution and treatment James Lucocq NHS Lothian 

6. 16:20 Targeting the host in Pancreatic Cancer: A Novel Combination Therapeutic from Bench to Bedside Keaton Jones University of Oxford  

1630 - 1645 

Pain Control in Chronic Pancreatitis Dr Bhavesh Raithatha

1645 – 1700 

Focus on Pancreatic Exocrine Insufficiency – PERT: When Who and How Much             Ms Rachel Caddy

1700 – 1715

Diagnostic testing for PEI: The metabolomic response Dr Sarah Powell-Brett

Close of day 1 Prof Andrew Hopper